We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+21.92%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.44B
AUM Growth
+$302M
Cap. Flow
+$191M
Cap. Flow %
13.26%
Top 10 Hldgs %
50.32%
Holding
229
New
57
Increased
37
Reduced
31
Closed
55

Top Buys

Rank Stock Value
1
NXTM
NxStage Medical Inc.
NXTM
+$24.7M
2
MDVN
MEDIVATION, INC.
MDVN
+$23.8M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.4M
4
STJ
St Jude Medical
STJ
+$16.6M
5
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$41.5M
2
HUM icon
Humana
HUM
+$20.1M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$12.4M
4
BAX icon
Baxter International
BAX
+$9.04M
5
XLRN
Acceleron Pharma
XLRN
+$6.5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.68%
2 Consumer Staples 0.52%
3 Consumer Discretionary 0.08%
4 Financials 0.04%
5 Industrials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASRT
26
DELISTED
Assertio
ASRT
$11.7M 0.81%
10,000
-833
-8% -$911K
EGRX
27
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$11.6M 0.81%
300,000
+112,785
+60% +$4.7M
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$140B
$11.2M 0.78%
130,000
-30,000
-19% -$2.59M
ALDX icon
29
Aldeyra Therapeutics
ALDX
$93.5M
$11M 0.77%
1,940,458
+700,000
+56% +$3.91M
WVE icon
30
Wave Life Sciences
WVE
$1.03B
$10.8M 0.75%
522,595
+346,595
+197% +$5.4M
SNDA icon
31
Sonida Senior Living
SNDA
$1.97B
$10.4M 0.72%
39,076
+2,767
+8% +$779K
HEDJ icon
32
PUT
WisdomTree Europe Hedged Equity Fund
HEDJ
$1.84B
$10.1M 0.7%
+400,000
New +$10.4M
ALDR
33
DELISTED
Alder Biopharmaceuticals
ALDR
$9.99M 0.69%
400,000
+25,000
+7% +$676K
DXCM icon
34
DexCom
DXCM
$33.6B
$9.93M 0.69%
500,696
+394,800
+373% +$6.72M
QURE icon
35
uniQure
QURE
$3.54B
$9.89M 0.69%
1,342,093
-100,000
-7% -$1.2M
TEVA icon
36
Teva Pharmaceuticals
TEVA
$44.4B
$9.85M 0.68%
196,000
-65,000
-25% -$3.46M
CRBP icon
37
Corbus Pharmaceuticals
CRBP
$219M
$9.57M 0.66%
106,667
+65,000
+156% +$5.1M
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$9.4M 0.65%
464,404
+60,000
+15% +$1.09M
AGTC
39
DELISTED
Applied Genetic Technologies Corporation
AGTC
$9.31M 0.65%
658,851
+8,260
+1% +$129K
RGNX icon
40
Regenxbio
RGNX
$588M
$8.79M 0.61%
1,099,213
+273,817
+33% +$3.04M
NERV icon
41
Minerva Neurosciences
NERV
$239M
$8.28M 0.57%
101,317
– –
CDTX
42
DELISTED
Cidara Therapeutics
CDTX
$8.17M 0.57%
39,643
+2,500
+7% +$605K
PFNX
43
DELISTED
Pfenex Inc.
PFNX
$8.04M 0.56%
960,877
– –
CTMX icon
44
CytomX Therapeutics
CTMX
$734M
$7.58M 0.53%
742,021
– –
EYPT icon
45
EyePoint Inc
EYPT
$431M
$7.54M 0.52%
266,500
– –
FPRX
46
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$7.01M 0.49%
169,439
-284,690
-63% -$12.4M
NEPT
47
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$6.88M 0.48%
4,822
– –
AKBA icon
48
Akebia Therapeutics
AKBA
$266M
$6.68M 0.46%
893,600
+28,600
+3% +$250K
RNAC icon
49
Cartesian Therapeutics
RNAC
$314M
$6.3M 0.44%
+15,000
New +$6.3M
MYOK
50
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$6.24M 0.43%
502,894
– –
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Perceptive Advisors held 229 positions worth $1.44B, up 27% from $1.14B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $191M of net new capital in Q2 2016, opening 57 new positions and adding to 37 existing holdings. Its largest new stake was NxStage Medical Inc.: 1,382,410 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 93% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Five Prime Therapeutics, Inc., an estimated $12.4M trimmed.

  • Perceptive Advisors's largest Q2 2016 buy was NxStage Medical Inc.: 1,382,410 shares worth $30M.
  • Perceptive Advisors added most to MEDIVATION, INC. in Q2 2016, an estimated $23.8M increase.
  • Perceptive Advisors's biggest Q2 2016 reduction was Five Prime Therapeutics, Inc., cutting an estimated $12.4M.
  • Perceptive Advisors fully exited Allergan plc in Q2 2016, selling an estimated $41.5M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $1.44B portfolio in Q2 2016.
  • Perceptive Advisors opened 57 new positions and closed 55 in Q2 2016.
  • Perceptive Advisors's portfolio value rose 27% quarter-over-quarter to $1.44B.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.